Exelixis
EXEL
#1579
Rank
C$15.64 B
Marketcap
$55.90
Share price
-0.36%
Change (1 day)
82.93%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): C$0.94 Billion

According to Exelixis's latest financial reports the company's current earnings are C$2.16 Billion. , an increase over its 2023 earnings that were of C$0.37 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 C$0.98 B164.69%
2023 C$0.37 B9.89%
2022 C$0.33 B-20.33%
2021 C$0.42 B124.82%
2020 C$0.18 B-67.14%
2019 C$0.57 B-11.94%
2018 C$0.65 B185.09%
2017 C$0.22 B-325.82%
2016 -C$0.11 Billion-58.12%
2015 -C$0.25 Billion-37.61%
2014 -C$0.39 Billion9.75%
2013 -C$0.36 Billion65.96%
2012 -C$0.22 Billion-291.63%
2011 C$0.11 B-195.59%
2010 -C$0.12 Billion-42.17%
2009 -C$0.21 Billion-18.98%
2008 -C$0.25 Billion-6.99%
2007 -C$0.27 Billion46.3%
2006 -C$0.19 Billion33.25%
2005 -C$0.14 Billion-30.92%
2004 -C$0.2 Billion44.29%
2003 -C$0.14 Billion12.86%
2002 -C$0.13 Billion22.79%
2001 -C$99.54 Million60.14%
2000 -C$62.16 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
C$6.04 B 511.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$11.51 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
C$21.71 B 2,096.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$12.16 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.68 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
C$25.29 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
C$10.06 B 918.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$64.98 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$42.12 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA